A Study for Patients With Schizophrenia

NCT00520923 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

654

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: LY2140023
DRUG: LY2140023
DRUG: LY2140023
DRUG: LY2140023
DRUG: Olanzapine
DRUG: Placebo
DRUG: Placebo

Sponsor

Eli Lilly and Company